| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TBM; leB; MUC5; mucin |
| Entrez GeneID | 4586 |
| clone | 6C9D11 |
| WB Predicted band size | 585.6kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MUC5AC (AA: 28-327) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MUC5AC抗体的代表性文献摘要(非真实文献，仅供示例参考)：
1. **《MUC5AC mucin expression in airway epithelial cells: Regulation and role in asthma pathogenesis》**
- 作者：Thornton DJ, et al.
- 摘要：研究MUC5AC在哮喘患者气道中的过表达机制，发现IL-13通过STAT6信号通路诱导MUC5AC分泌，其单克隆抗体检测显示黏液过度分泌与气道高反应性相关。
2. **《Development of a monoclonal antibody specific to human MUC5AC for gastrointestinal cancer diagnosis》**
- 作者：Chen J, et al.
- 摘要：报道一种新型MUC5AC单克隆抗体的开发，通过免疫组化验证其在胃癌和胰腺癌组织中的高特异性表达，提示其作为肿瘤标志物的潜在价值。
3. **《Comparative analysis of MUC5AC antibody performance in chronic obstructive pulmonary disease (COPD) models》**
- 作者：Kameyama K, et al.
- 摘要：比较两种商业化MUC5AC抗体(45M1和CLH2)在COPD患者痰液样本中的检测灵敏度，发现45M1抗体在定量黏液分泌程度时更具临床相关性。
4. **《MUC5AC glycosylation variants detected by novel antibodies correlate with respiratory viral infection outcomes》**
- 作者：Nagato H, et al.
- 摘要：利用针对MUC5AC糖基化表位的抗体，揭示不同糖型在呼吸道合胞病毒(RSV)感染中的差异表达，提示糖基化修饰影响宿主防御机制。
注：以上文献名为虚构，实际引用需通过PubMed或Google Scholar检索真实研究(可尝试关键词：MUC5AC antibody, airway/gastric mucus, immunohistochemistry)。
The MUC5AC antibody is a critical tool for studying the MUC5AC mucin, a gel-forming glycoprotein predominantly secreted by mucosal epithelial cells in the respiratory, gastrointestinal, and reproductive tracts. MUC5AC is a major component of mucus, playing essential roles in lubricating surfaces, trapping pathogens, and protecting underlying tissues. Its dysregulation is implicated in chronic respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease), gastrointestinal disorders (e.g., gastritis, colitis), and cancer (e.g., pancreatic, lung adenocarcinomas).
MUC5AC antibodies are widely used in immunohistochemistry (IHC), Western blot (WB), and ELISA to detect MUC5AC expression and localization in tissues or biofluids. These antibodies target specific epitopes of the MUC5AC protein core, with clones like 45M1. CLH2. and 2-11M being commonly utilized. Their applications span basic research (e.g., mucus biology, host-microbe interactions) and clinical diagnostics (e.g., monitoring airway inflammation, cancer biomarker studies).
Recent advancements emphasize antibody validation using MUC5AC-knockout models or siRNA to ensure specificity, as cross-reactivity with other mucins (e.g., MUC5B) can occur. Commercial antibodies are typically raised in mice, rabbits, or goats, with monoclonal versions offering higher consistency. Researchers also employ MUC5AC antibodies to explore therapeutic targets, such as inhibiting hypersecretion in cystic fibrosis or chronic bronchitis. Overall, MUC5AC antibodies remain indispensable for unraveling mucin-related pathophysiology and developing targeted interventions. (Word count: 249)
×
